vs
EXACT SCIENCES CORP（EXAS）与FIVE BELOW, INC（FIVE）财务数据对比。点击上方公司名可切换其他公司
FIVE BELOW, INC的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.0B vs $878.4M），FIVE BELOW, INC净利率更高（3.5% vs -9.8%，领先13.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-133.2M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -11.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Five Below是美国特色折扣礼品连锁品牌，2002年成立，总部位于宾夕法尼亚州费城，主要面向青少年消费群体，旗下绝大多数商品定价不超过5美元，另有少量精选商品最高定价40美元，目前在全美拥有超过1850家线下门店。
EXAS vs FIVE — 直观对比
营收规模更大
FIVE
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出0.1%
23.1%
净利率更高
FIVE
高出13.3%
-9.8%
自由现金流更多
EXAS
多$253.6M
$-133.2M
两年增速更快
EXAS
近两年复合增速
-11.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.0B |
| 净利润 | $-86.0M | $36.5M |
| 毛利率 | 70.1% | 33.8% |
| 营业利润率 | -9.4% | 4.2% |
| 净利率 | -9.8% | 3.5% |
| 营收同比 | 23.1% | 23.1% |
| 净利润同比 | 90.1% | 2063.9% |
| 每股收益（稀释后） | $-0.45 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFIVE
| Q4 25 | $878.4M | $1.0B | ||
| Q3 25 | $850.7M | $1.0B | ||
| Q2 25 | $811.1M | $970.5M | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $843.7M | ||
| Q3 24 | $708.7M | $830.1M | ||
| Q2 24 | $699.3M | $811.9M | ||
| Q1 24 | $637.5M | $1.3B |
净利润EXASFIVE
| Q4 25 | $-86.0M | $36.5M | ||
| Q3 25 | $-19.6M | $42.8M | ||
| Q2 25 | $-1.2M | $41.1M | ||
| Q1 25 | $-101.2M | $187.5M | ||
| Q4 24 | $-864.6M | $1.7M | ||
| Q3 24 | $-38.2M | $33.0M | ||
| Q2 24 | $-15.8M | $31.5M | ||
| Q1 24 | $-110.2M | $202.2M |
毛利率EXASFIVE
| Q4 25 | 70.1% | 33.8% | ||
| Q3 25 | 68.6% | 33.3% | ||
| Q2 25 | 69.3% | 33.4% | ||
| Q1 25 | 70.8% | 40.2% | ||
| Q4 24 | 69.0% | 30.6% | ||
| Q3 24 | 69.4% | 32.7% | ||
| Q2 24 | 69.8% | 32.5% | ||
| Q1 24 | 70.0% | 41.2% |
营业利润率EXASFIVE
| Q4 25 | -9.4% | 4.2% | ||
| Q3 25 | -3.0% | 5.1% | ||
| Q2 25 | -0.3% | 5.2% | ||
| Q1 25 | -13.6% | 17.7% | ||
| Q4 24 | -122.8% | -0.1% | ||
| Q3 24 | -5.6% | 5.0% | ||
| Q2 24 | -3.8% | 4.5% | ||
| Q1 24 | -16.7% | 20.1% |
净利率EXASFIVE
| Q4 25 | -9.8% | 3.5% | ||
| Q3 25 | -2.3% | 4.2% | ||
| Q2 25 | -0.1% | 4.2% | ||
| Q1 25 | -14.3% | 13.5% | ||
| Q4 24 | -121.2% | 0.2% | ||
| Q3 24 | -5.4% | 4.0% | ||
| Q2 24 | -2.3% | 3.9% | ||
| Q1 24 | -17.3% | 15.1% |
每股收益（稀释后）EXASFIVE
| Q4 25 | $-0.45 | $0.66 | ||
| Q3 25 | $-0.10 | $0.77 | ||
| Q2 25 | $-0.01 | $0.75 | ||
| Q1 25 | $-0.54 | $3.40 | ||
| Q4 24 | $-4.69 | $0.03 | ||
| Q3 24 | $-0.21 | $0.60 | ||
| Q2 24 | $-0.09 | $0.57 | ||
| Q1 24 | $-0.60 | $3.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $524.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.0B |
| 总资产 | $5.9B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASFIVE
| Q4 25 | $964.7M | $524.5M | ||
| Q3 25 | $1.0B | $670.2M | ||
| Q2 25 | $858.4M | $624.0M | ||
| Q1 25 | $786.2M | $528.8M | ||
| Q4 24 | $1.0B | $216.6M | ||
| Q3 24 | $1.0B | $327.7M | ||
| Q2 24 | $946.8M | $369.6M | ||
| Q1 24 | $652.1M | $460.1M |
股东权益EXASFIVE
| Q4 25 | $2.4B | $2.0B | ||
| Q3 25 | $2.5B | $1.9B | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.4B | $1.8B | ||
| Q4 24 | $2.4B | $1.6B | ||
| Q3 24 | $3.2B | $1.6B | ||
| Q2 24 | $3.2B | $1.6B | ||
| Q1 24 | $3.1B | $1.6B |
总资产EXASFIVE
| Q4 25 | $5.9B | $4.8B | ||
| Q3 25 | $5.9B | $4.6B | ||
| Q2 25 | $5.8B | $4.5B | ||
| Q1 25 | $5.7B | $4.3B | ||
| Q4 24 | $5.9B | $4.2B | ||
| Q3 24 | $6.7B | $4.0B | ||
| Q2 24 | $6.7B | $3.9B | ||
| Q1 24 | $6.4B | $3.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-80.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-133.2M |
| 自由现金流率自由现金流/营收 | 13.7% | -12.8% |
| 资本支出强度资本支出/营收 | 3.6% | 5.1% |
| 现金转化率经营现金流/净利润 | — | -2.19× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $323.0M |
8季度趋势，按日历期对齐
经营现金流EXASFIVE
| Q4 25 | $151.7M | $-80.1M | ||
| Q3 25 | $219.9M | $93.0M | ||
| Q2 25 | $89.0M | $132.7M | ||
| Q1 25 | $30.8M | $363.5M | ||
| Q4 24 | $47.1M | $-30.6M | ||
| Q3 24 | $138.7M | $71.3M | ||
| Q2 24 | $107.1M | $26.4M | ||
| Q1 24 | $-82.3M | $407.7M |
自由现金流EXASFIVE
| Q4 25 | $120.4M | $-133.2M | ||
| Q3 25 | $190.0M | $48.3M | ||
| Q2 25 | $46.7M | $96.5M | ||
| Q1 25 | $-365.0K | $311.4M | ||
| Q4 24 | $10.7M | $-111.0M | ||
| Q3 24 | $112.6M | $-32.4M | ||
| Q2 24 | $71.2M | $-61.4M | ||
| Q1 24 | $-120.0M | $304.6M |
自由现金流率EXASFIVE
| Q4 25 | 13.7% | -12.8% | ||
| Q3 25 | 22.3% | 4.7% | ||
| Q2 25 | 5.8% | 9.9% | ||
| Q1 25 | -0.1% | 22.4% | ||
| Q4 24 | 1.5% | -13.2% | ||
| Q3 24 | 15.9% | -3.9% | ||
| Q2 24 | 10.2% | -7.6% | ||
| Q1 24 | -18.8% | 22.8% |
资本支出强度EXASFIVE
| Q4 25 | 3.6% | 5.1% | ||
| Q3 25 | 3.5% | 4.4% | ||
| Q2 25 | 5.2% | 3.7% | ||
| Q1 25 | 4.4% | 3.7% | ||
| Q4 24 | 5.1% | 9.5% | ||
| Q3 24 | 3.7% | 12.5% | ||
| Q2 24 | 5.1% | 10.8% | ||
| Q1 24 | 5.9% | 7.7% |
现金转化率EXASFIVE
| Q4 25 | — | -2.19× | ||
| Q3 25 | — | 2.17× | ||
| Q2 25 | — | 3.22× | ||
| Q1 25 | — | 1.94× | ||
| Q4 24 | — | -18.13× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | — | 0.84× | ||
| Q1 24 | — | 2.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FIVE
暂无分部数据
